Drugs / MZ-1866
last change Dec 2025 re-read 3 minutes ago

MZ-1866

Developed for
Pitt-Hopkins syndrome
Investigated by
California Institute for Regenerative Medicine (CIRM) · Mahzi Therapeutics

Trials 1

2026202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT07135050 Dec 2025 → Mar 2029 expected Pitt-Hopkins syndrome Mahzi Therapeutics Recruiting No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as MZ-1866 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07135050 ↗